Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Colorectal Neoplasms 200Breast Neoplasms 124Carcinoma, Non-Small-Cell Lung 121Glioblastoma 93Neoplasms 75Ovarian Neoplasms 72Rectal Neoplasms 61Brain Neoplasms 59Lung Neoplasms 56Colonic Neoplasms 55Neoplasm Metastasis 51Glioma 49Carcinoma, Renal Cell 46Fallopian Tube Neoplasms 38Gliosarcoma 35Pancreatic Neoplasms 31Carcinoma, Hepatocellular 28Melanoma 26Adenocarcinoma of Lung 24Astrocytoma 21Stomach Neoplasms 20Uterine Cervical Neoplasms 16Recurrence 16Prostatic Neoplasms 16Liver Neoplasms 16Adenocarcinoma, Bronchiolo-Alveolar 16Esophageal Neoplasms 15Adenocarcinoma 15Carcinoma, Ovarian Epithelial 14Kidney Neoplasms 13

Interventions

Filgrastim 19Temozolomide 18Cyclophosphamide 16Carboplatin 15Etoposide 12Vincristine 11Peripheral Blood Stem Cell Transplantation 10Cisplatin 10Radiotherapy 9Irinotecan 9Thiotepa 8Granulocyte Colony-Stimulating Factor 7sonidegib 5Methotrexate 5sargramostim 4Vorinostat 4Magnetic Resonance Spectroscopy 4Lomustine 4Chemotherapy, Adjuvant 4Carmustine 4etoposide phosphate 3Topotecan 3Radiation 3Platinum 3Paclitaxel 3Oxaliplatin 3O(6)-benzylguanine 3Melphalan 3HhAntag691 3Granulocyte-Macrophage Colony-Stimulating Factor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Medulloblastoma × Bevacizumab × Clear all
NCT01217437 2021-07-23

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

National Cancer Institute (NCI)

Phase 2 Completed
108 enrolled 14 charts
CNS

Medulloblastoma, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

National Cancer Institute (NCI)

Phase 2 Completed
97 enrolled 35 charts
CNS

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡